Nab-paclitaxel or docetaxel; as alternatives to conventional paclitaxel for the treatment of metastatic breast cancer (MBC): cost utility analysis from the perspective of the United Kingdom (UK)

2008 ◽  
Vol 6 (7) ◽  
pp. 67
Author(s):  
G. Dranitsaris ◽  
M. Lidgren ◽  
J. Lundkvist ◽  
R. Coleman
Keyword(s):  
Breast Cancer ◽  
United Kingdom ◽  
Metastatic Breast Cancer ◽  
Metastatic Breast ◽  
Cost Utility ◽  
Cost Utility Analysis ◽  
Utility Analysis ◽  
The United Kingdom

A Cost-Utility Analysis of Second-Line Chemotherapy in Metastatic Breast Cancer

1996 ◽  
Vol 10 (5) ◽  
pp. 504-521 ◽  
Author(s):  
Robert Launois ◽  
Jeanne Reboul-Marty ◽  
Bernadette Henry ◽  
Jacques Bonneterre
Keyword(s):  
Breast Cancer ◽  
Metastatic Breast Cancer ◽  
Metastatic Breast ◽  
Cost Utility ◽  
Cost Utility Analysis ◽  
Second Line ◽  
Utility Analysis ◽  
Second Line Chemotherapy ◽  
Line Chemotherapy

scholarly journals PCN12: COST-UTILITY ANALYSIS COMPARING PACLITAXEL TO DOCETAXEL IN THE TREATMENT OF METASTATIC BREAST CANCER

2001 ◽  
Vol 4 (2) ◽  
pp. 88
Author(s):  
R Hauser ◽  
R Theriault ◽  
M Shepherd ◽  
K Lawson ◽  
J Wilson ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Metastatic Breast Cancer ◽  
Metastatic Breast ◽  
Cost Utility ◽  
Cost Utility Analysis ◽  
Utility Analysis
Sign in / Sign up

Export Citation Format

Share Document